Prestige Consumer Healthcare (PBH) Expected to Announce Quarterly Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH) is projected to issue its Q3 2026 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $1.16 per share and revenue of $286.9320 million for the quarter. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Individuals are encouraged to explore the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:30 AM ET.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, beating the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The firm had revenue of $274.11 million for the quarter, compared to analyst estimates of $257.14 million. During the same period last year, the firm earned $1.09 EPS. The business’s quarterly revenue was down 3.4% compared to the same quarter last year. On average, analysts expect Prestige Consumer Healthcare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock opened at $63.18 on Thursday. The company has a 50 day moving average of $62.32 and a 200-day moving average of $64.48. Prestige Consumer Healthcare has a 1-year low of $57.25 and a 1-year high of $90.04. The company has a current ratio of 3.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.55. The company has a market cap of $3.04 billion, a PE ratio of 15.68, a price-to-earnings-growth ratio of 2.01 and a beta of 0.40.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 719 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $60.00, for a total value of $43,140.00. Following the completion of the transaction, the vice president owned 42,329 shares of the company’s stock, valued at $2,539,740. This represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 1.40% of the company’s stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its stake in shares of Prestige Consumer Healthcare by 11.9% during the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock valued at $2,558,000 after acquiring an additional 3,200 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Prestige Consumer Healthcare by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock valued at $2,535,000 after purchasing an additional 1,289 shares during the period. Goldman Sachs Group Inc. raised its position in Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after purchasing an additional 120,965 shares during the last quarter. Jane Street Group LLC raised its position in Prestige Consumer Healthcare by 204.0% during the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock worth $9,010,000 after purchasing an additional 70,330 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after buying an additional 269 shares during the period. 99.95% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Oppenheimer cut their target price on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday, October 21st. Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Jefferies Financial Group dropped their price objective on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a research report on Monday, October 27th. Canaccord Genuity Group decreased their target price on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of “Moderate Buy” and an average target price of $85.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).